Quick-Trials for Novel Cancer Therapies: Exploratory Grants

The summary for the Quick-Trials for Novel Cancer Therapies: Exploratory Grants grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Quick-Trials for Novel Cancer Therapies: Exploratory Grants: Continuing progress in basic cancer research and drug development has led to discoveries of new agents or approaches for molecular targeting in novel cancer therapies. These new agents or approaches suppress tumor growth through multiple mechanisms such as cell cycle control, activation of tumor suppressor genes, essential signal pathway blockage, tumor vaccines, tumor microenvironment modification, etc. Rapid translation of these exciting discoveries into clinical practice requires timely support to accommodate the special needs of novel cancer therapy development. This Program Announcement (PA) is intended to provide investigators with rapid access to support for pilot, Phase I, and Phase II cancer clinical trials as well as support for patient monitoring and laboratory studies linked to a cancer clinical trial. Phase III trials are not excluded but such trials generally require greater resources and duration than available from an R21 award. Applications that do not propose a cancer clinical trial or patient monitoring or laboratory studies linked to a cancer clinical trial may be returned to applicants without being reviewed. The focus of this QUICK-TRIAL PA is on translational research in new agent development to ensure the timely exploitation of new cancer therapeutic approaches including the development of new cancer prevention agents. This PA is aimed at providing a new approach in the grant application process by offering a rapid turnaround from application submission to funding. Features of this initiative include a modular grant application and award process, inclusion of the clinical protocol within the grant application, and an accelerated peer review with the goal of issuing new awards within six months of application receipt. Inclusion of the complete clinical protocol within the PHS 398 grant application is intended to simplify the application process by eliminating the need to duplicate protocol details in the Research Plan section and to insure proper peer review of the application. In addition, QUICK-TRIAL applications do not require extensive preliminary data in the grant application and support exploratory translational and clinical research studies involving cancer prevention, chemotherapy and rapid development and application of novel clinical cancer therapies including image guided therapeutic procedures. Investigators may apply for a maximum of two years of funding support using the exploratory or developmental (R21) grant mechanism for up to $250,000 direct costs per year.
Federal Grant Title: Quick-Trials for Novel Cancer Therapies: Exploratory Grants
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-04-155
Type of Funding: Grant
CFDA Numbers: 93.39393.394
CFDA Descriptions: Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research
Current Application Deadline: No deadline provided
Original Application Deadline: Multiple Receipt Dates - See Link to Full Announce
Posted Date: Sep 08, 2004
Creation Date: Jun 09, 2006
Archive Date: Jun 02, 2006
Total Program Funding:
Maximum Federal Grant Award: $250,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: 93.395 -- Cancer Treatment Research
Applicants Eligible for this Grant
State governments City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled "Additional Information on Eligibility" for clarification) Public housing authorities/Indian housing authorities For profit organizations other than small businesses Special district governments Independent school districts Small businesses Public and State controlled institutions of higher education Private institutions of higher education County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized)
Additional Information on Eligibility
Eligible agencies of the Federal Government are eligible to apply. Foreign institutions are eligible to apply.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster FBOWebmaster@OD.NIH.GOV NIH OER Webmaster
More Grants from the National Institutes of Health
Limited Competition: AIDS Malignancy Consortium (AMC) (UM1 Clinical Trials Required)
Advancing Sustained/Extended Release for HIV Prevention (A-SER) (R01 Clinical Trial Not Al...
Resource-Related Research Projects for Development of Animal Models and Related Materials ...
Tailoring Interventions to Improve Preventive Health Service Use (R61/R33 Clinical Trial R...
Social Epigenomics Research Focused on Minority Health and Health Disparities (R01-Clinica...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2019 FederalGrants.com